γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T细胞可能是SCLC治疗的有价值靶点。
英文原题:CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.
CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.
本综述系统介绍了CAR-γδ T细胞作为可编程固有免疫哨兵的概念,创新性地提出克服传统CAR-αβ T细胞在实体瘤治疗和非恶性疾病背景下的多重局限性。
本综述系统阐述了CAR-γδ T细胞作为可编程固有免疫哨兵的概念,创新性地提出克服传统CAR-αβ T细胞在实体瘤治疗和非恶性疾病背景下的多重局限性。其核心创新在于将γδ T细胞的天然免疫特征——包括MHC非依赖性、抗耗竭表型可塑性及组织归巢能力——与CAR工程深度整合,有望在精准靶向、固有免疫激活与微环境调控之间产生协同效应。我们重点介绍了多信号整合、基因组编辑及通用型CAR-γδ T细胞平台开发等前沿技术的最新进展。与既往局限于单一疾病或信号通路的综述不同,本工作不仅总结了γδ T细胞的生物学特征,还提出了“以δT为中心”的工程设计原则,并构建了多疾病应用框架。在实体瘤中,该策略可能实现免疫抑制微环境的重塑并应对肿瘤异质性,而在非恶性疾病——包括纤维化、自身免疫性疾病和慢性感染——中,则支持组织稳态的恢复。我们提出,这一范式可将CAR-γδ T细胞的认知从传统效应工具转变为能够适应性响应疾病微环境的动态免疫枢纽。它为广泛疾病谱的基础研究和临床转化提出了新的概念与技术框架。
This review systematically introduces the concept of CAR-γδ T cells as programmable innate immune sentinels, innovatively proposing to overcome multiple limitations of conventional CAR-αβ T cells in both solid tumor therapy and non-malignant disease contexts. The core innovation lies in the deep integration of γδ T cells' natural immune features - including MHC-independent, anti-exhaustion phenotypic plasticity, and tissue-homing capability - with CAR engineering, potentially yielding synergistic effects between precise targeting, innate immune activation, and microenvironment modulation. We highlight recent advances in cutting-edge technologies such as multi-signal integration, genome editing, and the development of off-the-shelf CAR-γδ T cell platforms. Unlike previous reviews that focus narrowly on a single disease or signaling pathway, this work not only summarizes the biological characteristics of γδ T cells but also proposes a "δT-centric" engineering design principle and constructs a multi-disease application framework. In solid tumors, this approach may enable the remodeling of the immunosuppressive microenvironment and addresses tumor heterogeneity, whereas in non-malignant diseases-including fibrosis, autoimmune disorders, and chronic infections-it supports tissue homeostasis restoration. We propose that this paradigm could shift the perception of CAR-γδ T cells from conventional effector tools to dynamic immune hubs capable of responding adaptively to disease microenvironments. It proposes a novel conceptual and technological framework for both basic research and clinical translation across a broad spectrum of diseases.
MEMBER ACCOUNT
登录成功会直接打开下一页。